These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

293 related items for PubMed ID: 21596119

  • 1. The conflict between in vitro release studies in human biorelevant media and the in vivo exposure in rats of the lipophilic compound fenofibrate.
    Do TT, Van Speybroeck M, Mols R, Annaert P, Martens J, Van Humbeeck J, Vermant J, Augustijns P, Van den Mooter G.
    Int J Pharm; 2011 Jul 29; 414(1-2):118-24. PubMed ID: 21596119
    [Abstract] [Full Text] [Related]

  • 2. Analysis of the enhanced oral bioavailability of fenofibrate lipid formulations in fasted humans using an in vitro-in silico-in vivo approach.
    Fei Y, Kostewicz ES, Sheu MT, Dressman JB.
    Eur J Pharm Biopharm; 2013 Nov 29; 85(3 Pt B):1274-84. PubMed ID: 23500116
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Solid self-nanoemulsifying drug delivery system (S-SNEDDS) of darunavir for improved dissolution and oral bioavailability: In vitro and in vivo evaluation.
    Inugala S, Eedara BB, Sunkavalli S, Dhurke R, Kandadi P, Jukanti R, Bandari S.
    Eur J Pharm Sci; 2015 Jul 10; 74():1-10. PubMed ID: 25845633
    [Abstract] [Full Text] [Related]

  • 7. Self-microemulsifying smaller molecular volume oil (Capmul MCM) using non-ionic surfactants: a delivery system for poorly water-soluble drug.
    Bandivadeka MM, Pancholi SS, Kaul-Ghanekar R, Choudhari A, Koppikar S.
    Drug Dev Ind Pharm; 2012 Jul 10; 38(7):883-92. PubMed ID: 22087760
    [Abstract] [Full Text] [Related]

  • 8. Combining in vitro and in silico methods for better prediction of surfactant effects on the absorption of poorly water soluble drugs-a fenofibrate case example.
    Berthelsen R, Sjögren E, Jacobsen J, Kristensen J, Holm R, Abrahamsson B, Müllertz A.
    Int J Pharm; 2014 Oct 01; 473(1-2):356-65. PubMed ID: 24997410
    [Abstract] [Full Text] [Related]

  • 9. Gastrointestinal behavior of nano- and microsized fenofibrate: In vivo evaluation in man and in vitro simulation by assessment of the permeation potential.
    Hens B, Brouwers J, Corsetti M, Augustijns P.
    Eur J Pharm Sci; 2015 Sep 18; 77():40-7. PubMed ID: 26004010
    [Abstract] [Full Text] [Related]

  • 10. Selection of a discriminant and biorelevant in vitro dissolution test for the development of fenofibrate self-emulsifying lipid-based formulations.
    Pestieau A, Krier F, Brouwers A, Streel B, Evrard B.
    Eur J Pharm Sci; 2016 Sep 20; 92():212-9. PubMed ID: 27169683
    [Abstract] [Full Text] [Related]

  • 11. Design of lipid-based formulations for oral administration of poorly water-soluble drug fenofibrate: effects of digestion.
    Mohsin K.
    AAPS PharmSciTech; 2012 Jun 20; 13(2):637-46. PubMed ID: 22547370
    [Abstract] [Full Text] [Related]

  • 12. Enhancement of oral bioavailability of fenofibrate by solid self-microemulsifying drug delivery systems.
    Kim GG, Poudel BK, Marasini N, Lee DW, Hiep TT, Yang KY, Kim JO, Yong CS, Choi HG.
    Drug Dev Ind Pharm; 2013 Sep 20; 39(9):1431-8. PubMed ID: 23046292
    [Abstract] [Full Text] [Related]

  • 13. A novel nanomatrix system consisted of colloidal silica and pH-sensitive polymethylacrylate improves the oral bioavailability of fenofibrate.
    Jia Z, Lin P, Xiang Y, Wang X, Wang J, Zhang X, Zhang Q.
    Eur J Pharm Biopharm; 2011 Sep 20; 79(1):126-34. PubMed ID: 21658449
    [Abstract] [Full Text] [Related]

  • 14. Effect of different polysorbates on development of self-microemulsifying drug delivery systems using medium chain lipids.
    Shah A, Thool P, Sorathiya K, Prajapati H, Dalrymple D, Serajuddin ATM.
    Drug Dev Ind Pharm; 2018 Feb 20; 44(2):215-223. PubMed ID: 29057677
    [Abstract] [Full Text] [Related]

  • 15. IVIVC in oral absorption for fenofibrate immediate release tablets using a dissolution/permeation system.
    Buch P, Langguth P, Kataoka M, Yamashita S.
    J Pharm Sci; 2009 Jun 20; 98(6):2001-9. PubMed ID: 18855916
    [Abstract] [Full Text] [Related]

  • 16. Polymeric Precipitation Inhibitors Promote Fenofibrate Supersaturation and Enhance Drug Absorption from a Type IV Lipid-Based Formulation.
    Suys EJA, Chalmers DK, Pouton CW, Porter CJH.
    Mol Pharm; 2018 Jun 04; 15(6):2355-2371. PubMed ID: 29659287
    [Abstract] [Full Text] [Related]

  • 17. Characterisation of fenofibrate dissolution delivered by a self-microemulsifying drug-delivery system.
    Wei JD, Ho HO, Chen CH, Ke WT, Chen ET, Sheu MT.
    J Pharm Pharmacol; 2010 Dec 04; 62(12):1685-96. PubMed ID: 21054394
    [Abstract] [Full Text] [Related]

  • 18. A simplified method to screen for in-vivo performance of oral lipid formulations.
    Kilic M, Dressman J.
    J Pharm Pharmacol; 2014 May 04; 66(5):615-23. PubMed ID: 24313318
    [Abstract] [Full Text] [Related]

  • 19. Comparison of in vitro tests at various levels of complexity for the prediction of in vivo performance of lipid-based formulations: case studies with fenofibrate.
    Griffin BT, Kuentz M, Vertzoni M, Kostewicz ES, Fei Y, Faisal W, Stillhart C, O'Driscoll CM, Reppas C, Dressman JB.
    Eur J Pharm Biopharm; 2014 Apr 04; 86(3):427-37. PubMed ID: 24184675
    [Abstract] [Full Text] [Related]

  • 20. Design of lipid-based formulations for oral administration of poorly water-soluble drugs: precipitation of drug after dispersion of formulations in aqueous solution.
    Mohsin K, Long MA, Pouton CW.
    J Pharm Sci; 2009 Oct 04; 98(10):3582-95. PubMed ID: 19130605
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.